Nebuliser Guidance and Monographs - Adult
PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension)
ARIKAYCE® liposomal 590 mg nebuliser dispersion - Dosing and Management
ARIKAYCE Instructions For Use
How To Use Pari eRapid Nebulizer System ? - YouTube
Nebulizer Market Size to Surpass USD 1,202.5 Million by 2029, exhibiting a CAGR of 4.8%
These highlights do not include all the information needed to use ARIKAYCE safely and effectively. See full prescribing information for ARIKAYCE. ARIKAYCE® (amikacin liposome inhalation suspension), for oral inhalation use Initial U.S.
Presentation Title (Insert the Title AAPS approved and that is displayed in the promotional materials for this meeting)
Arikayce Dosage Guide - Drugs.com
ARIKAYCE® Prescription and Arikares® Support Program Enrollment Form
New Drug Product: Arikayce - MPR
eFlow Technology Platform - PARI
Pharmaceutical liposomal delivery—specific considerations of innovation and challenges - Biomaterials Science (RSC Publishing) DOI:10.1039/D2BM01252A
Resources for HCPs | ARIKAYCE® (amikacin liposome inhalation suspension)
What to expect when starting ARIKAYCE®
ARIKAYCE - Cancer Therapy Advisor
Global Inhalation Therapy Nebulizer Market Is Likely To Grow At A CAGR Value Of Around 7.5% By 2028
Lamira - PARI
Inhalation mit dem Lamira® Inhalationssystem - YouTube
Taking ARIKAYCE® | ARIKAYCE® (amikacin liposome inhalation suspension)
Track Record - PARI
Inhalation mit dem Lamira® Inhalationssystem - YouTube
207356Orig1s000
Texas Children's Hospital
